Rupa currently serves as the Director of Enterprise Science and Innovation Partnerships at Thermo Fisher Scientific. In this role, she has the responsibility of creating and managing strategic partnerships with global BioPharma and Biotech customers in the area of Cell and Gene Therapy. Prior to this, she was the Head of Technical Operations where she worked closely with customers to conduct technology transfer and process optimization activities related to GMP manufacturing of cell-based therapies. She has over 12 years of expertise in GMP manufacturing for a variety of cell types and the use of closed/automated manufacturing platforms and technologies. In her past global role at Thermo Fisher Scientific, she served as a Global Strategic Alliance Leader in Regenerative Medicine for early adoption of disruptive technologies. She has served in various leadership roles in academic institutes and start-up companies. At Ligand Pharmaceuticals, she was part of the team that designed novel hematopoietic screening assays for erythropoietin and thrombopoietin in partnership with GlaxoSmithKline, a part of the program that led to development of Promacta®. Rupa holds a Master’s degree in Biology from Loyola University and a Doctorate from Harvard University.
Rupa Pike, PhD
Director, Enterprise Science & Innovation Partnerships, Thermo Fisher Scientific